NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.47 +0.47 (+0.59%) GOLD FUTURES
2,317.40 +6.40 (+0.28%) DOW
38,191.93 +288.64 (+0.76%) Bitcoin GBP
47,366.87 +1,234.60 (+2.68%)
MRNA Jan 2025 280.000 call
| Previous close | 0.5600 |
| Open | 0.5100 |
| Bid | 0.5000 |
| Ask | 0.9200 |
| Strike | 280.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.5100 - 0.5600 |
| Contract range | N/A |
| Volume | |
| Open interest | 780 |
- Yahoo Finance Video
Moderna CEO on the changing COVID market: Pandemic to endemic
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy developing updated coronavirus vaccines for the 2024-2025 season and recently announced an expansion into the Brazilian market. As the coronavirus pandemic has shifted toward an endemic, Bancel explains how Moderna continues to innovate, sharing a positive outlook on phase two data for a combination flu and coronavirus vaccine. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
- Yahoo Finance Video
Apple, Novo Nordisk earnings, jobless claims: What to watch
A number of companies release their quarterly earning reports on Thursday, including Apple (AAPL), Novo Nordisk (NVO), Shell (SHEL), ConocoPhillips (COP), Cigna (CI), Coinbase (COIN), Moderna (MRNA), DraftKings (DKNG), Kellanova (K), United States Steel (X), and more. On the economic front, jobless claims for the week ending on April 27 will be released. Economists expect claims to rise to 212,000 from 207,000 the prior week. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Nicholas Jacobino
Investor's Business DailyIs Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Moderna stock broke out of a cup-with-handle base after its first-quarter sales and earnings report. Is MRNA stock a buy right now?
